Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Scott A. Stuart"'
Autor:
Andrew J, Kavran, Scott A, Stuart, Kristyn R, Hayashi, Joel M, Basken, Barbara J, Brandhuber, Natalie G, Ahn
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 119(12)
Patients with melanoma receiving drugs targeting BRAFV600E and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression. Based on preclinical studies, intermittent treatment involvin
Publikováno v:
Molecular & Cellular Proteomics. 14:1599-1615
Inhibitors of oncogenic B-RAF(V600E) and MKK1/2 have yielded remarkable responses in B-RAF(V600E)-positive melanoma patients. However, the efficacy of these inhibitors is limited by the inevitable onset of resistance. Despite the fact that these inhi
Publikováno v:
Complementary Therapies in Clinical Practice. 21:94-100
Background Up to 20% of women experience postpartum depression (PPD). PPD is associated with anxiety and poor health-related quality of life (HRQOL). Efficacious treatments are critical; many women with PPD prefer complementary therapies. Thus, the c
Autor:
Natalie G. Ahn, Christopher C. Ebmeier, Scott A. Stuart, Thomas Lee, Joel Basken, William M. Old, Andrew J. Kavran
Publikováno v:
Molecularcellular proteomics : MCP. 17(4)
The BRAF-MKK1/2-ERK1/2 pathway is constitutively activated in response to oncogenic mutations of BRAF in many cancer types, including melanoma. Although small molecules that inhibit oncogenic BRAF and MAP kinase kinase (MKK)1/2 have been successful i
Autor:
Scott, L. Stuart
Publikováno v:
The British Medical Journal, 1961 Mar . 1(5228), 788-790.
Externí odkaz:
https://www.jstor.org/stable/20352712
Autor:
Scott, L. Stuart
Publikováno v:
The British Medical Journal, 1956 Jan . 1(4960), 200-203.
Externí odkaz:
https://www.jstor.org/stable/20334289